Loading...

IKT INHIBIKASE THERAPEUTICS INC Management Changes 8-K Filing

NHBK

KT

INHIBIKASE THERAPEUTICS INC

(IKT)

2025 8-K

Public Offering Announcement

Clinical Trial Advancement

Financial Results Announced

Financial Update

Financial Statements

Management Changes

Financial Results

Merger Agreement

Trial Results Update

Share Increase Approval

ATM Agreement Termination

Private Placement Closed

Private Placement Deal

Company Presentation

Special Meeting Approval

Annual Meeting of Stockholders

Securities Purchase Agreement

Presentation and Arbitratio...

Letter to Stockholders

Appointment of CFO

Management Change

Compliance Regained

Reverse Stock Split

Annual Meeting Results

Presentations to Investors

No Exposure to Silicon Vall...

Options Awarded

Securities Purchase Agreeme...

External Links:

On April 11, 2025, Garth Lees-Rolfe resigned as CFO of Inhibikase Therapeutics, and David McIntyre was appointed as the new CFO on April 14, 2025, with a salary of $485,000 and stock options totaling 3,142,967 shares.

AI Assistant

INHIBIKASE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.